600329.SH
达仁堂
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 35.72
+1.05%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.0B | 4.9B | 7.3B | 8.2B | 8.2B |
| Cost of Revenue | 1.2B | 1.3B | 3.8B | 4.6B | 5.0B |
| Gross Profit | 3.7B | 3.6B | 3.5B | 3.6B | 3.3B |
| Operating Expenses | |||||
| R&D Expense | 193.8M | 189.8M | 162.4M | 184.6M | 153.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 396.3M | 391.5M | 458.5M | 381.6M | 377.9M |
| Selling & Marketing Expense | 2.0B | 2.0B | 2.0B | 2.1B | 2.0B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.7B | 2.7B | 2.7B | 2.8B | 2.5B |
| Cost and Expenses | 3.9B | 3.9B | 6.5B | 7.4B | 7.5B |
| Operating Income (EBIT) | 2.5B | 2.5B | 2.6B | 1.1B | 980.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 2.5B | 2.5B | 2.6B | 1.1B | 980.2M |
| Income Tax Expense | 383.0M | 376.7M | 363.6M | 126.7M | 106.9M |
| Bottom Line | |||||
| Net Income | 2.2B | 2.1B | 2.2B | 986.7M | 861.8M |
| Earnings from Cont. Ops | 2.2B | 2.1B | 2.2B | 968.7M | 873.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.2B | 2.1B | 2.2B | 986.7M | 861.8M |
| Per Share | |||||
| Basic EPS | CN¥2.83 | CN¥2.77 | CN¥2.90 | CN¥1.28 | CN¥1.12 |
| Diluted EPS | CN¥2.83 | CN¥2.77 | CN¥2.89 | CN¥1.28 | CN¥1.11 |
| Revenue Per Share | CN¥6.46 | CN¥6.39 | CN¥9.50 | CN¥10.67 | CN¥10.72 |
| Shares | |||||
| Basic Shares Outstanding | 770.6M | 769.3M | 768.7M | 770.9M | 769.5M |
| Diluted Shares Outstanding | 770.6M | 769.3M | 768.7M | 770.9M | 769.5M |
| Profitability Metrics | |||||
| EBITDA | — | 2.6B | 2.7B | 1.2B | 1.1B |
| D&A | — | 122.3M | 123.8M | 129.6M | 118.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026